Showing 7 posts of 7 posts found.

Lundbeck HQ

Lundbeck gets go-ahead for US and EU licence expansions

February 4, 2016
Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine

Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …

Avanir image

Otsuka buys Avanir for $3.5 billion

December 3, 2014
Sales and Marketing Abilify, Alzheimer's, Alzheimer’s, Nuedexta, Otsuka, Parkinson's, Parkinson’s, avanir

Otsuka is to buy Avanir Pharmaceuticals for $3.5 billion as it looks to make up for the imminent patent expiry …


Alkermes schizophrenia drug shines in Phase III

April 8, 2014
Medical Communications, Research and Development, Sales and Marketing Abilify, Alkermes, aripiprazole, schizophrenia

Alkermes’ investigational schizophrenia drug has met its primary endpoint in a pivotal trial, leading the firm to seek regulatory approval …

Abilify image

NICE thumbs-up for Abilify

June 7, 2013
Sales and Marketing Abilify, BMS, NICE, Otsuka

Adolescents who suffer from bipolar disorder should be treated on the NHS with Otsuka Pharmaceuticals’ Abilify, according to draft guidance …

Lundbeck and Otsuka to collaborate in CNS

November 11, 2011
Research and Development, Sales and Marketing Abilify, CNS, Lundbeck, Otsuka

Lundbeck and Otsuka have signed a major collaborative deal to sell and develop up to five CNS drugs, including a …

NICE decides to back Abilify in schizophrenia

January 27, 2011
Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia

NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …

NICE won’t approve Abilify without more data

September 13, 2010
Sales and Marketing Abilify, BMS, NICE

NICE is unlikely to approve Bristol-Myers Squibb’s schizophrenia drug Abilify unless the company can provide more data on its clinical …

Latest content